Gulam Mohiyuddin Shirol

Dr. Gulam Mohiyuddin Shirol

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
SSSundus Shukar
Sundus Shukar
IHIltaf Hussain
Iltaf Hussain
AIAhamed Iqbal
Ahamed Iqbal
ARAli Rahimi
Ali Rahimi
GSGulam Mohiyuddin Shirol
Gulam Mohiyuddin Shirol
YFYu Fang
Yu Fang
Objective South Asia bears a high cancer burden, low universal health coverage and high out-of-pocket expenditure. Access to anticancer medicines is challenging and is influenced by determinants—National Essential Medicines List (NEML), registration and local production—yet these are rarely evaluated. This study evaluates these determinants in eight South Asian countries. Design Multimethod study using a document analysis phase and semistructured interviews. Setting Eight South Asian countries (Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka) for document analysis, with stakeholder interviews conducted in six countries, excluding Bhutan and Maldives. Participants Data were collected from eight regulatory authorities and 30 interviews with drug supply chain stakeholders across six South Asian countries. Main outcome measures The inclusion of 67 anticancer medicines from the 2023 WHO Essential Medicines List (EML) into NEML, their registration and local production, along with macrolevel indicators and stakeholders’ perspectives regarding them. Results The median number of medicines included in NEMLs, registered and locally produced was 23.5, 45 and 6.5, respectively. Local production correlated positively with NEML inclusion (ρ=0.884, p=0.004) and negatively with healthcare expenditure (r = −0.732, p=0.039). Three countries listed >50% of the WHO EML medicines on their NEMLs; six had >50% registered. Local production remained limited, with imports dominating supply. Qualitative analysis identified three key barriers to improving availability: financial constraints, a weak regulatory system and insufficient strategic planning. Conclusions Access to anticancer medicines is constrained by systemic misalignment between NEML inclusion, registration and local production, undermined by weak regulatory coordination, limited strategic planning and financial constraints. Strengthening regulatory coordination, improving registration efficiency and supporting regional production strategies aligned with guided WHO guidance may help improve equitable access to cancer medicines in the region.

15 June 2023 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
MGMadhusoodan M Gonenavar
Madhusoodan M Gonenavar
VKVishal Kulkarni
Vishal Kulkarni
RPRashmi Prasad
Rashmi Prasad
GSGulam Mohiyuddin Shirol
Gulam Mohiyuddin Shirol
NSNida Khanum Sirdesai
Nida Khanum Sirdesai
Phlebitis caused by high concentration amiodarone infusion is a rather uncommon occurrence. Phlebitis is one of the most reported causes of high concentration amiodarone continuous infusion in bradycardia. We reported a case of patient with continuous infusion of amiodarone induced phlebitis. Patient felt pain along the path of cannula, erythema, induration, palpable venous cord. Visual Infusion Phlebitis Score was assessed and VIP Score was found to be 4. We suspected the incidence of phlebitis due to high concentration and continuous infusion of IV amiodarone. In this case report, we would like to discuss about the standard protocol of IV administration of amiodarone, evaluation of phlebitis by Visual Infusion Phlebitis Score, and management of Phlebitis. Keywords: Visual Infusion Phlebitis Score, amiodarone, phlebitis, tachyarrhythmia, peripheral administration.

22 August 2025 in Medicina
Verified
Journal Article
Open access
PDF file
IHIWASAKI HIDEKI
IWASAKI HIDEKI
GSGulam Mohiyuddin Shirol
Gulam Mohiyuddin Shirol
TMTomoji Maeda
Tomoji Maeda
MWMineo Christopher Watanabe
Mineo Christopher Watanabe
TTTokuko Takajo
Tokuko Takajo
Yoshikazu MatsudaYoshikazu Matsuda
Yoshikazu Matsuda
Background and Objectives: Kumazasa extract (KZExt) is a food product obtained by steam extraction of Kumazasa (Sasa senanensis and Sasa kurilensis) leaves under high temperature and pressure. It contains abundant polyphenols, including trans-p-coumaric acid and ferulic acid, as well as xylooligosaccharides. In this study, we investigated the antibacterial, anti-viral, and anti-inflammatory effects of KZExt in vitro and in vivo. Materials and Methods: The anti-oxidant, antibacterial, and anti-viral effects of KZExt were assessed in vitro. Anti-oxidant activity was evaluated based on the scavenging of •OH, •O2− and 1O2. Antibacterial effects were assessed by determining the minimum inhibitory concentration (MIC) using a microdilution method. Anti-influenza activity was measured via plaque formation in MDCK cells. Anti-inflammatory effects were assessed by measuring interleukin (IL)-1β inhibition in lipopolysaccharide (LPS)-stimulated RAW264.7 cells. In vivo, KZExt was administered once (30 min before) in a formalin-induced inflammation model to evaluate pain-related behavior. In the LPS-induced inflammation model, KZExt was administered for five days before LPS injection. Behavioral changes and cytokine levels were assessed 24 h later via the open field test and cytokine quantification. Results: In vitro, KZExt showed antibacterial, anti-influenza, and anti-oxidant effects, and suppressed LPS-induced IL-1β production. In vivo, it significantly reduced the second phase of formalin-induced pain behavior. In the LPS model, although behavioral changes were unaffected, KZExt suppressed IL-6 and interferon-γ production. Conclusions: The antibacterial, anti-viral, and anti-inflammatory effects of KZExt were confirmed in vitro and in vivo. Notably, the anti-inflammatory effect suggests potential immunomodulatory activity. These findings indicate that KZExt may help suppress smoldering inflammation and inflammation associated with various diseases through its combined antibacterial, anti-viral, and immunomodulatory actions.